Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Migalastat Hydrochloride Patent Expiration

Migalastat Hydrochloride is Used for managing left ventricular mass index in Fabry disease patients. It was first introduced by Amicus Therapeutics Us Llc in its drug Galafold on Aug 10, 2018.


Migalastat Hydrochloride Patents

Given below is the list of patents protecting Migalastat Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Galafold US11833164 Methods of treating Fabry disease in patients having a mutation in the GLA gene Jan 11, 2042 Amicus Therap Us
Galafold US11633388 Methods of treating Fabry patients having renal impairment Mar 25, 2039 Amicus Therap Us
Galafold US11622962 Methods of treating Fabry patients having renal impairment Mar 17, 2039 Amicus Therap Us
Galafold US11642334 Methods of treating Fabry patients having renal impairment Feb 20, 2039 Amicus Therap Us
Galafold US11826360 Methods of treating Fabry patients having renal impairment Feb 16, 2039 Amicus Therap Us
Galafold US11357784 Use of migalastat for treating Fabry disease in pregnant patients Feb 06, 2039 Amicus Therap Us
Galafold US11903938 Methods of treating Fabry patients having renal impairment Aug 17, 2038 Amicus Therap Us
Galafold US10251873 Methods of treating fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10471053 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10792278 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10792279 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10799491 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10806727 Methods of treating fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10849889 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10849890 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10857141 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10857142 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10874655 Methods of treating fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10874656 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10874657 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11278536 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11278537 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11278538 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11278539 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11278540 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11304940 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11357761 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11357762 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11357763 Methods of treating fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11357764 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11357765 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11376244 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11389436 Methods of treating fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11389437 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11426396 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11458128 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11612593 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11612594 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11633387 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11666564 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11786516 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US11813255 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US12042488 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US12042489 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US12042490 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US12109205 Methods of treating Fabry patients having renal impairment May 30, 2038 Amicus Therap Us
Galafold US10076514 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene Mar 15, 2037 Amicus Therap Us
Galafold US11234972 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene Mar 15, 2037 Amicus Therap Us
Galafold USRE48608 Method to predict response to pharmacological chaperone treatment of diseases Oct 20, 2031 Amicus Therap Us
Galafold US10813921 Method to predict response to pharmacological chaperone treatment of diseases Feb 12, 2029 Amicus Therap Us
Galafold US8592362 Method to predict response to pharmacological chaperone treatment of diseases Feb 12, 2029 Amicus Therap Us
Galafold US9095584 Method to predict response to pharmacological chaperone treatment of diseases Feb 12, 2029 Amicus Therap Us
Galafold US10525045 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr 28, 2028 Amicus Therap Us
Galafold US10925866 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr 28, 2028 Amicus Therap Us
Galafold US11033538 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr 28, 2028 Amicus Therap Us
Galafold US9999618 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr 28, 2028 Amicus Therap Us
Galafold US10383864 Methods for treatment of Fabry disease May 16, 2027 Amicus Therap Us
Galafold US10406143 Methods for treatment of fabry disease May 16, 2027 Amicus Therap Us
Galafold US11241422 Methods for treatment of Fabry disease May 16, 2027 Amicus Therap Us
Galafold US9000011 Methods for treatment of Fabry disease May 16, 2027 Amicus Therap Us
Galafold US9480682 Methods for treatment of Fabry disease May 16, 2027 Amicus Therap Us
Galafold US9987263 Methods for treatment of Fabry disease May 16, 2027 Amicus Therap Us



Migalastat Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List